Debt-free Balance SheetZero reported debt provides enduring financial flexibility: it lowers bankruptcy and covenant risk, preserves capacity to absorb R&D shocks, and makes equity- or partner-based financing less risky. Over months, this structural strength supports runway management during clinical development.

Recurring Stem Cell Banking RevenueA commercial stem cell banking arm generates predictable, contract-based cash inflows that can partially offset volatile R&D spending. This recurring service revenue is a durable operational anchor, improving short-to-medium-term funding stability while clinical programs progress.

Consistent Revenue GrowthSustained top-line growth indicates continued market demand for the company’s services and beginning commercial traction. Over a multi-month horizon this trend supports scaling of the service business and enhances leverage potential once R&D transitions toward partnering or commercialization.

Bears Say

Deep, Persistent UnprofitabilitySevere and persistent losses reflect an unmet path to operating profitability. Structurally, negative gross margins and very large negative net margins constrain reinvestment capacity, increase reliance on external funding, and heighten execution and dilution risk while clinical programs continue.

Sustained Negative Cash FlowOngoing free cash flow burn of tens of millions is a durable pressure on the business: it shortens runway, forces recurrent financing or partnership dependency, and limits the firm’s ability to independently advance costly clinical programs without dilutive capital events.

Eroding Equity / Dilution RiskMaterial erosion of equity over several years signals cumulative losses and capital raises, raising the probability of further dilution. Over months this weakens the capital base, reduces financial cushions for setbacks, and can impair the company’s bargaining position in partnerships or financings.

65G FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was €0.05 and its highest was €0.29 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is €14.75M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is May 28, 2026 which is in 98 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on Oct 30, 2025. The company reported -€0.007 earnings per share for the quarter, beating the consensus estimate of -€0.009 by €0.002.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 111,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -€0.007 in its last earnings report, beating expectations of -€0.009. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in DE:65G

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.